Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions.
The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year
Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director
SALT LAKE CITY , Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...
SALT LAKE CITY , Oct. 30, 2025 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...
SALT LAKE CITY , Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ®  (Nasdaq: SERA), focused on improving maternal and neonatal health by providing...
SALT LAKE CITY , Aug. 28, 2025 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing...
SALT LAKE CITY , Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative...
SALT LAKE CITY , July 29, 2025 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by...
/PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative...